These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 16048982

  • 21. In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis model.
    Robaux MA, Dube L, Caillon J, Bugnon D, Kergueris MF, Navas D, Le Conte P, Baron D, Potel G.
    J Antimicrob Chemother; 2001 May; 47(5):617-22. PubMed ID: 11328773
    [Abstract] [Full Text] [Related]

  • 22. Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics.
    Vinks AA, Brimicombe RW, Heijerman HG, Bakker W.
    J Antimicrob Chemother; 1997 Jul; 40(1):125-33. PubMed ID: 9249216
    [Abstract] [Full Text] [Related]

  • 23. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections.
    McKinnon PS, Paladino JA, Schentag JJ.
    Int J Antimicrob Agents; 2008 Apr; 31(4):345-51. PubMed ID: 18313273
    [Abstract] [Full Text] [Related]

  • 24. Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa.
    Lu Q, Yang J, Liu Z, Gutierrez C, Aymard G, Rouby JJ, Nebulized Antibiotics Study Group.
    Am J Respir Crit Care Med; 2011 Jul 01; 184(1):106-15. PubMed ID: 21474643
    [Abstract] [Full Text] [Related]

  • 25. Cure of Pseudomonas aeruginosa infection in neutropenic patients by continuous infusion of ceftazidime.
    Daenen S, de Vries-Hospers H.
    Lancet; 1988 Apr 23; 1(8591):937. PubMed ID: 2895853
    [No Abstract] [Full Text] [Related]

  • 26. Fever and neutropenia during intensive chemotherapy.
    Klastersky J.
    Ann Oncol; 1993 Aug 23; 4(7):603-6. PubMed ID: 8363991
    [No Abstract] [Full Text] [Related]

  • 27. Optimized dosage and frequency of cefozopran for patients with febrile neutropenia based on population pharmacokinetic and pharmacodynamic analysis.
    Nomura K, Morikawa N, Ikawa K, Ikeda K, Fujimoto Y, Shimizu D, Taniguchi K, Shimura K, Kanbayashi Y, Komori T, Matsumoto Y, Fujita N, Shimazaki C, Taniwaki M.
    J Antimicrob Chemother; 2008 Apr 23; 61(4):892-900. PubMed ID: 18276604
    [Abstract] [Full Text] [Related]

  • 28. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
    Ludwig E, Konkoly-Thege M, Kuti JL, Nicolau DP.
    Int J Antimicrob Agents; 2006 Nov 23; 28(5):433-8. PubMed ID: 17046212
    [Abstract] [Full Text] [Related]

  • 29. [Investigation on optimal regimen of ceftazidime against infection caused by Pseudomonas aeruginosa using Monte Carlo simulation].
    Mikamo H.
    Jpn J Antibiot; 2007 Dec 23; 60(6):387-93. PubMed ID: 18447208
    [Abstract] [Full Text] [Related]

  • 30. Vancomycin serum concentration during febrile neutropenia in patients with acute myeloid leukemia.
    Hochart C, Berthon C, Corm S, Gay J, Cliquennois M, Tricot S, Alfandari S.
    Med Mal Infect; 2011 Dec 23; 41(12):652-6. PubMed ID: 22056376
    [Abstract] [Full Text] [Related]

  • 31. Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection.
    Moriarty TF, McElnay JC, Elborn JS, Tunney MM.
    Pediatr Pulmonol; 2007 Nov 23; 42(11):1008-17. PubMed ID: 17902147
    [Abstract] [Full Text] [Related]

  • 32. [Imipenem/cilastatin versus ceftazidime-amikacin in the treatment of febrile neutropenic patients].
    Pérez C, Sirham M, Labarca J, Grebe G, Lira P, Oliva J, Duhalde M, Ocqueteau M, Acuña G.
    Rev Med Chil; 1995 Mar 23; 123(3):312-20. PubMed ID: 8525170
    [Abstract] [Full Text] [Related]

  • 33. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy.
    Freifeld A, Marchigiani D, Walsh T, Chanock S, Lewis L, Hiemenz J, Hiemenz S, Hicks JE, Gill V, Steinberg SM, Pizzo PA.
    N Engl J Med; 1999 Jul 29; 341(5):305-11. PubMed ID: 10423464
    [Abstract] [Full Text] [Related]

  • 34. Prospective study of empiric monotherapy with ceftazidime for low-risk grade IV febrile neutropenia after cytotoxic chemotherapy in cancer patients.
    Chernobelski P, Lavrenkov K, Rimar D, Riesenberg K, Schlaeffer F, Ariad S, Mermershtain W.
    Chemotherapy; 2006 Jul 29; 52(4):185-9. PubMed ID: 16675902
    [Abstract] [Full Text] [Related]

  • 35. Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion.
    Burgess DS, Summers KK, Hardin TC.
    Clin Ther; 1999 Nov 29; 21(11):1882-9. PubMed ID: 10890260
    [Abstract] [Full Text] [Related]

  • 36. Optimization of dose and dose regimen of biapenem based on pharmacokinetic and pharmacodynamic analysis.
    Takata T, Aizawa K, Shimizu A, Sakakibara S, Watabe H, Totsuka K.
    J Infect Chemother; 2004 Apr 29; 10(2):76-85. PubMed ID: 15160299
    [Abstract] [Full Text] [Related]

  • 37. A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit.
    Mouton JW, Punt N, Vinks AA.
    Clin Ther; 2005 Jun 29; 27(6):762-72. PubMed ID: 16117983
    [Abstract] [Full Text] [Related]

  • 38. Empirical antimicrobial therapy in pediatric patients with neutropenia and fever. Risk factors for treatment failure.
    Miranda-Novales MG, Belmont-Martinez L, Villasis-Keever MA, Penagos-Paniagua M, Bernaldez-Rios R, Solorzano-Santos F.
    Arch Med Res; 1998 Jun 29; 29(4):331-5. PubMed ID: 9887552
    [Abstract] [Full Text] [Related]

  • 39. Empiric monotherapy in neutropenia: a realistic goal?
    Del Favero A, Bucaneve G, Menichetti F.
    Scand J Infect Dis Suppl; 1995 Jun 29; 96():34-7. PubMed ID: 7652501
    [Abstract] [Full Text] [Related]

  • 40. Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group.
    Tamura K.
    Int J Antimicrob Agents; 2005 Dec 29; 26 Suppl 2():S123-7; discussion S133-40. PubMed ID: 16249072
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.